Casi Pharmaceuticals Inc (CASI)
2.15 x 1 2.42 x 4
Post-market by (Cboe BZX)
2.15 -0.05 (-2.27%) 03/28/25 [NASDAQ]
2.15 x 1 2.42 x 4
Post-market 2.15 unch (unch) 10:31 ET
for Fri, Mar 28th, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 84,205 | 43,490 | 27,093 | 5,131 | 10,670 |
| Marketable Securities | 912 | N/A | N/A | N/A | N/A |
| Receivables | N/A | N/A | N/A | N/A | 24 |
| Inventories | 283 | N/A | N/A | N/A | N/A |
| TOTAL | $92,565 | $43,812 | $27,449 | $5,569 | $11,022 |
| Non-Current Assets | |||||
| PPE Net | 1,751 | 1,047 | 230 | 219 | 262 |
| Intangibles | 18,785 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 310 | 242 | 35 | 38 | 26 |
| TOTAL | $20,846 | $1,289 | $264 | $257 | $288 |
| Total Assets | $113,411 | $45,101 | $27,713 | $5,826 | $11,310 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 968 | 4,316 | 1,065 | 884 | 755 |
| Accrued Expenses | 1,406 | 746 | 251 | 170 | 164 |
| TOTAL | $3,873 | $5,062 | $1,316 | $1,054 | $919 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 1,499 | 1,491 | 1,465 | 1,390 |
| aiOther Non-Current Liabilities | 74 | 0 | 4,122 | 9,395 | 9,423 |
| TOTAL | $74 | $1,499 | $5,614 | $10,860 | $10,813 |
| Total Liabilities | $3,947 | $6,561 | $6,929 | $11,914 | $11,732 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 9,572 | 7,964 | 6,020 | 4,258 | 3,245 |
| Common Shares | 954 | 699 | 603 | 325 | 325 |
| Retained earnings | -478,941 | -452,702 | -441,932 | -432,478 | -425,272 |
| Other shareholders' equity | -1,261 | -34 | -34 | -34 | -34 |
| TOTAL | $109,464 | $38,540 | $20,784 | $-6,087 | $-422 |
| Total Liabilities And Equity | $113,411 | $45,101 | $27,713 | $5,826 | $11,310 |